For instance, giredestrant in combination with palbociclib is being compared with letrozole plus palbociclib in the treatment of metastatic ER+ HER2− breast cancer in the first-line settings (persevERA Breast Cancer, NCT04546009). This evidence concerns the gene ESR1 and breast carcinoma.